Ascentage Pharma announced that the Center for Drug Evaluation of China’s National Medical Product Administration has approved a global registrational Phase III study of the company’s novel drug candidate olverembatinib, in patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had failed prior systemic treatment.
